In this small, single-center cohort, an unusual clustering of early symptomatic UTIs was observed among patients initiating vedolizumab. These findings are observational and hypothesis-generating, and no causal relationship can be inferred. They highlight the importance of real-world pharmacovigilance and the need for larger, multicenter studies to clarify whether such infection patterns reflect contextual clustering or reproducible safety signals influenced by regional epidemiological factors.
Yousef VatanParast (Sun,) studied this question.